OPUS GENETICS ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 1/2 CLINICAL TRIAL OF OPGX-RDH12 GENE THERAPY FOR RARE INHERITED CHILDHOOD BLINDNESS

Reuters · 3d ago

Please log in to view news